Experienced in Undifferentiated Connective Tissue Disease (UCTD)

Dr. Vivek Nagaraja

Rheumatology
13400 E Shea Blvd, 
Scottsdale, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
13400 E Shea Blvd, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vivek Nagaraja is a Rheumatologist in Scottsdale, Arizona. Dr. Nagaraja is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Scleroma, and Scleredema. Dr. Nagaraja is currently accepting new patients.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in MI
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Mayo Clinic Building SCT-1
13400 E Shea Blvd, Scottsdale, AZ 85259

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Biological
Study Drug: Brentuximab vedotin
Study Phase: Phase 1/Phase 2
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drugs: Pirfenidone, Mycophenolate Mofetil
Study Phase: Phase 2
A Multi-Center Cluster Randomized Controlled Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making
A Multi-Center Cluster Randomized Controlled Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
View 6 Less Clinical Trials

35 Total Publications

The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis.
The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis.
Journal: Journal of clinical medicine
Published: April 28, 2025
Similar Doctors
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ravi M. Bhalla
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ravi M. Bhalla
Rheumatology

Bhsm Rehabilitation LLC

5605 W Eugie Ave, Suite 212and215, 
Glendale, AZ 
 (13.2 miles away)
602-865-5830
Languages Spoken:
English, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ravi Bhalla is a Rheumatologist in Glendale, Arizona. Dr. Bhalla is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Palindromic Rheumatism, Fibromyalgia, Rheumatoid Arthritis (RA), and Postmenopausal Osteoporosis. Dr. Bhalla is currently accepting new patients.

Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Vijayabhanu Mahadevan
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Vijayabhanu Mahadevan
Rheumatology

American Arthritis And Rheumatology Associates - Az PLLC

12665 W Smokey Dr, Suite 140, 
Surprise, AZ 
 (21.6 miles away)
623-219-4040
Languages Spoken:
English, Hindi, Tamil
See accepted insurances
Offers Telehealth

Vijayabhanu Mahadevan is a Rheumatologist in Surprise, Arizona. Dr. Mahadevan is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Rhizomelic Pseudopolyarthritis.

Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Rajbir Gulati
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Rajbir Gulati
Rheumatology

American Arthritis And Rheumatology Associates - Az PLLC

12665 W Smokey Dr, Suite 140, 
Surprise, AZ 
 (21.6 miles away)
623-219-4040
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajbir Gulati is a Rheumatologist in Surprise, Arizona. Dr. Gulati is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Psoriasis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Rhizomelic Pseudopolyarthritis. Dr. Gulati is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagaraja's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile